Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells

Leukemia Research

Volumn 32, Issue 9, 2008, Pages 1366-1373

  Haritunians, Talin ^a   Gueller, Saskia ^a   Zhang, Ling ^a   Badr, Riem ^a   Yin, Dong ^a   Xing, Hongtao ^a   Fung, Ming Chiu ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Actin cytoskeleton; Cucurbitacin; Leukemia; Myelodysplastic syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CUCURBITACIN B; F ACTIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL ENLARGEMENT; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTINUCLEAR CELL; MYELODYSPLASTIC SYNDROME; POLYMERIZATION; PRIORITY JOURNAL;

ACTINS; ANTIGENS, CD11B; APOPTOSIS; BONE MARROW; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOSKELETON; GRANULOCYTES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; S PHASE; TRITERPENES;

EID: 43049175018     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.01.019     Document Type: Article

References (17)

1. Chen J.C., Chiu M.H., Nie R.L., Cordell G.A., and Qiu S.X. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep 22 3 (Jun 2005) 386-399
2. Jayaprakasam B., Seeram N.P., Nair M.G., and Anticancer. Anticancer antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 189 1 (Jan 10 2003) 11-16
3. Tannin-Spitz T., Grossman S., Dovrat S., Gottlieb H.E., and Bergman M. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol 73 1 (Jan 1 2007) 56-67
4. Xia X., Hou F., Li J., Ke Y., and Nie H. Two novel proteins bind specifically to trichosanthin on choriocarcinoma cell membrane. J Biochem 139 4 (Apr 2006) 725-731
5. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., and Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63 6 (March 15) (2003) 1270-1279
6. Sun J., Blaskovich M.A., Jove R., Livingston S.K., Coppola D., and Sebti S.M. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24 20 (May 5) (2005) 3236-3245
7. Smit H.F., van den Berg A.J., Kroes B.H., Beukelman C.J., Quarles van Ufford H.C., van D.H., et al. Inhibition of T-lymphocyte proliferation by cucurbitacins from Picrorhiza scrophulariaeflora. J Nat Prod 63 9 (September) (2000) 1300-1302
8. Duncan M.D., and Duncan K.L. Cucurbitacin E targets proliferating endothelia. J Surg Res 69 1 (April) (1997) 55-60
9. Witkowski A., Woynarowska B., and Konopa J. Inhibition of the biosynthesis of deoxyribonucleic acid, ribonucleic acid and protein in HeLa S3 cells by cucurbitacins, glucocorticoid-like cytotoxic triterpenes. Biochem Pharmacol 33 7 (April 1) (1984) 995-1004
10. Peters R.R., Baier K.P., Siqueira-Junior J.M., da Silva Rocha J.C., Marques B.M., de Albuquerque R.R., et al. Nitric oxide and cyclooxygenase may participate in the analgesic and anti-inflammatory effect of the cucurbitacins fraction from Wilbrandia ebracteata. Life Sci 73 17 (September 12) (2003) 2185-2197
11. Duncan K.L., Duncan M.D., Alley M.C., and Sausville E.A. Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol 52 10 (November 22) (1996) 1553-1560
12. Graness A., Poli V., and Goppelt-Struebe M. STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I. Biochem Pharmacol 72 1 (June 28) (2006) 32-41
13. Shi X., Franko B., Frantz C., Amin H.M., and Lai R. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol 135 1 (October) (2006) 26-32
14. Haritunians T., Mori A., O'Kelly J., Luong Q.T., Giles F.J., and Koeffler H.P. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21 2 (February) (2007) 333-339
15. Kumagai T., O'Kelly J., Said J.W., and Koeffler H.P. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 95 12 (June 18) (2003) 896-905
16. Hisatake J., O'Kelly J., Uskokovic M.R., Tomoyasu S., and Koeffler H.P. Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 97 8 (April 15) (2001) 2427-2433
17. Lee E., Shelden E.A., and Knecht D.A. Formation of F-actin aggregates in cells treated with actin stabilizing drugs. Cell Motil Cytoskel 39 2 (1998) 122-133